Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 172   

Articles published

MRK 51.03 +0.08 (0.16%)
price chart
Bionomics Announces Extension of Strategic Collaboration with Merck & Co., Inc ...
ADELAIDE, Australia, Oct. 8, 2015 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous ...
REFILE-BRIEF-Bionomics announces extension of strategic collaboration with ...  Reuters
Merck and Co Latest FDA Approval Looks Good: UBS
Merck & Co., Inc. (NYSE:MRK) received a second approval for its immune-oncology drug, Keytruda. Last week the Food and Drug Administration (FDA) granted expanded approval to Keytruda for treating the most common form of lung cancer, both squamous ...
FDA Expands Approval Of Merck's Keytruda To Lung Cancer  Medical Daily
FDA Approves Merck's Keytruda for Advanced Lung Cancer  Tech Times
Zacks Short Term Rating on Merck & Company, Inc. (NYSE:MRK)
Merck & Company, Inc. (NYSE:MRK) has received a short term rating of sell from research analysts at Zacks with a rank of 4. The company has been rated an average of 2 by 14 Wall Street Analysts.
Large Inflow of Money Witnessed in Merck & Company, Inc.  American Trade Journal
Merck & Co. Lowered to Sell at Zacks (MRK)  Dakota Financial News
Are Amgen, Inc. And Merck and Co CETP A Threat To PCSK-9
Amgen Inc. (NASDAQ:AMGN) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) recently revolutionized the cholesterol market with their new treatments, which belong to the new class of drugs called PCSK9 inhibitors.
Bristol-Myers Squibb Co Headed To Trample Merck & Co., Inc. In Immunotherapy ...
At the moment, the dominant player is Merck & Co., Inc. (NYSE:MRK), who's Keytruda currently leads the field. The success of Bristol-Myers Squibb Co.
Pfizer Inc, Merck and Co. Also To Blame For US Drug Price Hikes
An exorbitant price hike by a small, obscure biotech, Turing Pharmaceutical, triggered a massive political debate on specialty pharma drug pricing in the last week of September.
This Coule Be Merck & Co., Inc. (MRK)'s Most Important News Today
Merck & Company (MRK) shares inched lower in trading Friday despite a move by the U.S. Food and Drug Administration to grant accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced non-small cell lung cancer.
Market Update: Merck & Co Inc (NYSE:MRK) - U.S. FDA expands approval of ...  Jutia Group (blog)
See Which Of The Latest 13F Filers Holds Merck & Co.
At Holdings Channel , we have reviewed the latest batch of the 20 most recent 13F filings for the 09/30/2015 reporting period, and noticed that Merck & Co., Inc (Symbol: MRK) was held by 13 of these funds. When hedge fund managers appear to be thinking ...
Movements of Healthcare Stocks: Merck & Co., Inc. (NYSE:MRK), Eli Lilly (NYSE ...
At the time of Market beginning, Merck & Co., Inc. (NYSE:MRK) initiated business at $50.46. The company rose 2.31% after overall traded volume of 14.54 million shares with market capitalization of $140.27 billion.
Fear These 3 Biotech Stocks: Merck & Co. Inc. (NYSE:MRK), Eli Lilly and ...  Seneca Globe
Merck & Company, Inc. (NYSE:MRK) Analyst Price Target
Merck & Company, Inc. (NYSE:MRK) should head towards $64.91 per share according to 11 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $57 per share.
Company Shares of Merck & Company, Inc. (NYSE:MRK) Rally 1.09%  News Watch International
Merck & Co. Coverage Initiated by Analysts at Societe Generale (MRK)  The Legacy